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ABSTRACT: In the present study, small-angle X-ray scattering (SAXS) and
static light scattering (SLS) have been used to study the solution properties and
self-interaction of recombinant human serum albumin (rHSA) molecules in
three pharmaceutically relevant buﬀer systems. Measurements are carried out
up to high protein concentrations and as a function of ionic strength by adding
sodium chloride to probe the role of electrostatic interactions. The eﬀective
structure factors (Seff) as a function of the scattering vector magnitude q have
been extracted from the scattering proﬁles and ﬁt to the solution of the
Ornstein−Zernike equation using a screened Yukawa potential to describe the
double-layer force. Although only a limited q range is used, accurate ﬁts
required including an electrostatic repulsion element in the model at low ionic
strength, while only a hard sphere model with a tunable diameter is necessary
for ﬁtting to high-ionic-strength data. The ﬁt values of net charge agree with
available data from potentiometric titrations. Osmotic compressibility data
obtained by extrapolating the SAXS proﬁles or directly from SLS measurements has been ﬁt to a 10-term virial expansion for
hard spheres and an equation of state for hard biaxial ellipsoids. We show that modeling rHSA as an ellipsoid, rather than a
sphere, provides a much more accurate ﬁt for the thermodynamic data over the entire concentration range. Osmotic virial
coeﬃcient data, derived at low protein concentration, can be used to parameterize the model for predicting the behavior up to
concentrations as high as 450 g/L. The ﬁndings are especially important for the biopharmaceutical sector, which require
approaches for predicting concentrated protein solution behavior using minimal sample consumption.
■ INTRODUCTION
In formulation of proteinaceous drugs, one of the main
concerns is the physical stability of the drug molecule. Proteins
at high concentrations tend to self-associate, potentially leading
to high-viscosity solutions or aggregation. Modiﬁcations such
as oxidation or adsorption to the vial are additional concerns in
formulation strategies. If the three-dimensional structure of a
protein is not conserved, this could lead to degradation, loss of
activity, and the formation of new epitopes, which could
induce an immunological response. Finally, the formulation of
course needs to be compatible with the route of admin-
istration. All of these challenges generate issues during
production, for ensuring prolonged shelf-life of a biopharma-
ceutical, and in administration, which all set high demands on
the formulation.1
Human serum albumin (HSA) is, with a blood concen-
tration of 35−50 mg/mL, the most abundant plasma protein
comprising more than half the amount of proteins in the blood
plasma. HSA has many important physiological functions and,
for instance, regulates the colloidal osmotic pressure and
transports endogenous physiological metabolites and exoge-
nous ligands, such as fatty acids, hormones, bile acids, and
drugs.2−4 These properties have drawn much interest from the
pharmaceutical industry and particularly in clinical applica-
tions.5 HSA’s pharmacokinetic properties are utilized in drug-
delivery systems, and HSA’s ability to increase the solution
stability of other proteins is used in drug formulations.
In formulations, HSA is used as a stabilizer, preventing
aggregation, as an antiadsorption agent, or as an antioxidant6,7
and was traditionally widely used in pharmaceutical products
such as Avonex and Epogen. However, due to severe safety
issues associated with infection of patients with human
immunodeﬁciency virus from plasma-derived constituents in
medicine in the 1980s and the 1990s and later with the
occurrence of Creutzfeldt−Jakob disease transferred from
infected cows, it became increasingly diﬃcult to get regulatory
approval of drugs containing constituents of mammalian origin.
The use of serum-derived HSA was therefore limited. With the
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development of recombinant HSA (rHSA) derived from yeast
(Recombumin, Albumedix Ltd.), the interest has resurfaced in
the last decade and an increasing number of modern
pharmaceuticals containing rHSA like the trivalent subunit
vaccine M-M-RII and the tetravalent subunit vaccine ProQuad
have been marketed.
The use of albumin to stabilize protein-based drugs at low
concentration was established decades ago and is expected to
function via competitive inhibition of the protein-based drug
adsorption to other materials.8 At protein-based drug
concentrations less than 0.1 mg/mL, adsorption of protein-
based drugs to the available air−liquid and solid−liquid
surfaces in the primary packaging material will result in
depletion and/or lead to surface-induced degradation of the
active component. Hence, prevention of drug adsorption is
thus essential and can be mitigated by addition of a nonionic
detergent or by addition of HSA.
In contrast to this, the mechanism of action for preventing
aggregation is speculative for formulations with protein-based
drug concentrations above 1 mg/mL. Here, rHSA is used in
concentrations ranging from a few mg/mL to all the way up to
around 50 mg/mL. At these higher concentrations, the
aggregation of proteins is a complex process. One commonly
recognized mechanism is the nonspeciﬁc eﬀects of steric
exclusion, where the protein molecules in question are
excluded from the volume occupied by other protein species.
With increasing concentration, the volume of the solution
available to proteins is restricted. In terms of thermodynamics,
the entropy of a crowded solution is signiﬁcantly reduced and
hence the free energy of the proteins increases. The system
reacts to this by association of proteins to reduce the exclusion
of volume.9,10 However, steric exclusion is not entirely
nonspeciﬁc, and in many cases, the aggregation propensity of
proteins depends on their speciﬁc structures and local
environments.11,12 It has been shown for solutions of
monoclonal antibodies at relatively high concentrations that
HSA prevents liquid−liquid phase separation, which is often
preempted by aggregation or crystallization.13 Understanding
the stabilizing ability of rHSA requires ﬁrst elucidating the
thermodynamic behavior in rHSA-only solutions from low to
high protein concentrations. In dilute protein solutions, the
osmotic pressure (or osmotic compressibility) of the solution
is determined by the osmotic second virial coeﬃcient B22,
which is commonly obtained by static light scattering
(SLS).14−20 The pH and ionic strength dependence of B22
provides an insight into the intermolecular forces underpinning
the solution behavior.16−18,21−25 Measurements for solutions
of either rHSA or bovine serum albumin (BSA) have been
rationalized in terms of potential of mean force models that
describe the protein−protein interaction using an excluded
volume potential and the electric double-layer force from the
Derjaguin−Landau−Verwey−Overbeek (DLVO) theory and,
in some cases, an additional short-ranged protein−protein
attraction.26−29
Early studies by Tardieu et al.30−34 on α-crystallin found in
the eye lens showed how small-angle X-ray scattering (SAXS)
could be used for examination of the interaction of proteins in
highly concentrated solutions. The α-crystallin interaction was
modeled using the renormalized mean spherical approximation
with the electric double-layer potential from the DLVO theory
and a hard core potential (the excluded volume eﬀect).31
Due to its high solubility in aqueous solutions, serum
albumin has been used as a model system to study high protein
concentrations (up to 500 mg/mL) in buﬀer-free solution with
and without salts.35−41 SAXS experiments indicate that
monovalent salts such as NaCl in general have a screening
eﬀect. Under low-ionic-strength conditions, measured struc-
ture factors were ﬁt to the mean spherical approximation,
which is based on a spherical model using only the electric
double-layer potential from the DLVO theory, whereas at
higher salt concentrations (greater than 1 M), the structure
factors reﬂected the presence of a short-ranged attraction
between proteins.41 The authors postulated the existence of a
repulsive hydration force to prevent phase separation, which
would ordinarily occur in the presence of an attractive
interaction. Small-angle neutron scattering studies of HSA
interacting in D2O with and without NaCl (1.08 M) were ﬁt by
Sjöberg and Mortensen to Monte Carlo simulations using an
ellipsoidal shape to describe the protein.42,43 The ﬁtting
required including an additional square well repulsive potential
at low salt conditions and a short-ranged repulsive Yukawa
potential at high salt concentration, but there was no evidence
for a short-ranged protein−protein attraction.
In the present study, to shed more insight into the observed
stabilizing eﬀect, we have used SAXS and SLS to study the
solution properties and self-interaction of rHSA molecules in
three pharmaceutically relevant buﬀer systems with diﬀerent
ionic strengths. The mean spherical approximation has been
used to ﬁt structure factor curves measured by SAXS and we
have compared a hard sphere versus ellipsoidal model for
reproducing osmotic compressibility curves up to 315 g/L
obtained from SLS and SAXS. We show that rHSA behavior in
solutions at NaCl concentrations up to 500 mM can be
adequately explained without invoking the existence of any
short-ranged attraction, where the excluded volume eﬀects are
more accurately captured using an ellipsoidal model rather
than a spherical one. We ﬁnd the only eﬀect of changing the
formulation buﬀer is to alter the strength of electrostatic
interactions due to diﬀerences in the solution pH and ionic
strength.
■ THEORY
The next section provides an overview of the protein−protein
interaction model, focusing on how the model is characterized
from measurement of the osmotic second virial coeﬃcient, and
its relationship to the structure factor at high protein
concentrations. Furthermore, we provide the relationships
between the SLS and SAXS measurements and the osmotic
compressibility in terms of the measured structure factor and
emphasize the limitations of using SAXS to probe the behavior
of anisotropic shaped particles such as rHSA.
Protein−Protein Interaction Theory. The two-body
potential of mean force, w(r), where r is the center-to-center
separation between proteins, provides the input into models
for predicting thermodynamic properties and the equilibrium
solution microstructure. w(r) corresponds to an interaction
free energy averaged over the relative orientations between a
pair of proteins as well as the solvent degrees of freedom.
Previous studies on BSA and HSA under low- to moderate-
ionic-strength conditions indicate that the protein−protein
interaction is well described using a hard sphere repulsion in
combination with an electrostatic contribution.41,44 A theoreti-
cal model for the electrostatic terms is given by the electric
double-layer potential derived within the DLVO theory, which
treats the protein as a uniformly charged sphere immersed in a
dielectric continuum containing point charges (e.g., salt ions).
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For low surface potentials, a reasonable approximation for the
two-body interaction free energy is given by eq 1
β
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where Z corresponds to the protein valency, σ is an eﬀective
hard sphere diameter, and β is the dimensionless inverse
temperature 1/kbT, where kb is the Boltzmann constant. The
excluded volume contribution to the interaction potential is
controlled by the parameter σ, which controls the distance of
closest approach between a pair of proteins. The range of the
electrostatic interactions is controlled by κ, the inverse Debye−
Hückel screening length
κ βεε= e N I2 /( )2 A 0 (2)
where I is the ionic strength of the solution, e is the electronic
charge, ε0 is the vacuum permittivity, ε is the dielectric
constant of water, and NA is Avogadro’s number. λB
corresponds to the Bjerrum length λ πβεε= e /(4 )B 2 0 , which
is the separation between a pair of ions when the Coulomb
energy is equal to thermal energy.
A commonly used method for characterizing simpliﬁed
models for w(r) is through measurements of the osmotic
second virial coeﬃcient, B22
v , obtained here through static light
scattering. B22
v is related to w(r) through an average over r
given by
∫ β π= [ − − ]∞B w r r r12 1 exp( ( )) 4 d22v 0
2
(3)
Equation 3 can be further simpliﬁed by carrying out the
integration over r between 0 and σ to give
∫ β π= + [ − − ]
σ
∞
B B w r r r
1
2
1 exp( ( )) 4 d22
v
22
hs 2
(4)
where B22
hs corresponds to the excluded volume interaction of a
hard sphere of diameter σ, which is equal to 4 times the sphere
volume (2πσ3/3). The integral on the right-hand side of eq 4
includes the contributions of all forces except for excluded
volume, which are collectively referred to as soft potentials.
SAXS experiments provide information about the spatial
protein density distribution in terms of the static structure
factor. For an isotropic system, S(q) is related to the Fourier
transform of the pair distribution function g(r) by
∫πρ= + [ − ]S q r r qrq g r( ) 1 4 d
sin( )
( ) 1
(5)
where ρ is the protein molecular density and q is the
momentum transfer vector magnitude q = 4π sin θ/λ, where λ
is the wavelength of the X-rays and 2θ is the scattering angle.
The pair distribution function corresponds to the normalized
density for the centers of protein molecules in a spherical shell
located at r with thickness Δr and volume 4πr2Δr about a
protein molecule ﬁxed at the origin. The Ornstein−Zernike
(OZ) equation, when combined with an appropriate closure
relation, can be used to determine g(r) or equivalently S(q) in
terms of the interaction potential, w(r). In this work, we have
used an analytical solution for the OZ equation based on the
mean spherical approximation for the Yukawa interaction
model, which has the same mathematical form as the electric
double-layer potential given in eq 1.27
SLS Theory and Analysis. The measured quantity in an
SLS experiment termed the excess Rayleigh ratio R̅θ is equal to
the light scattered by the protein sample minus the scattering
from the solvent mixture at the same chemical potential as the
protein solution. The relationship to the osmotic compressi-
bility of the solution for a single solute in a mixed solvent is
given by45−47
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where c is the protein mass concentration, Mw is the protein
molecular weight, and S(0) is the static structure factor
evaluated in the limit of q→ 0, which is related to the osmotic
compressibility of the protein solution. K is an optical constant
equal to 2π2n0
2/(NAλ
4), where n0 is the refractive index of the
solvent. The refractive index increment (∂n/∂c) is at constant
temperature and chemical potential of solvent components,
which is obtainable through dialysis equilibrium experiments.
We use a literature value approximately equal to 0.185 mL/g
measured for BSA in solutions at low to moderate tonicities.48
Equation 6 is only valid when there is no angle dependence of
the scattered light, which is a good approximation when the
characteristic correlation length scale is less than 1/20th the
wavelength of the incident light.
The experimental osmotic second virial coeﬃcient, denoted
here as B22 = NAB22
v /Mw
2 , is determined from SLS using only
low-protein-concentration data. In this case, the osmotic
compressibility is expanded in a virial expansion, which gives
in the low-protein-concentration limit
∂ ∂
̅
= +
θ
Kc n c
R M
B c
( / ) 1
2
2
w
22
(7)
B22 is determined from a linear ﬁt to eq 7 from 10
measurements with protein concentration varying between 2
and 20 g/L. The regressed slope is equal to 2B22, and the
inverse of the y-intercept is equal to Mw. In the Results and
Discussion section, the reported error bars correspond to the
standard error in the slope estimation.
SAXS Theory. A SAXS experiment is used to measure the
scattering intensity per unit volume, I(q), as a function of the
scattering vector q. The total scattering intensity is given by49
ϕ ρ= ΔI q V P q S q( ) ( ) ( ) ( )2 p eff (8)
where P(q) is the form factor deﬁned as P(q) = ⟨|Fj(q,Ωj)|2⟩Ωj/
(Δρ)2Vp2, Δρ is the excess scattering length density of the
protein, and ϕ is the protein volume fraction. For a particle
with a homogeneous electron density distribution, the
scattering length Fj(q,Ωj) is given by an integral over the
particle volume Vp
∫ ρΩ = Δ [ · ]q q R RF( , ) exp i dj j j j (9)
where Rj corresponds to the spatial coordinate within the
particle relative to the particle center of mass and Ωj deﬁnes
the particle orientation in the coordinate system of the
laboratory reference frame.
The proﬁle Seff(q) can be obtained either by using an
analytical expression for the form factor or by normalizing the
X-ray scattering proﬁle with data obtained at low protein
concentration, which is the approach used here. At low protein
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concentration, there are no orientational or intermolecular
correlations between particles and Seff(q) = 1 so that
50
ϕ ρ= ΔI q V P q( ) ( ) ( )low low
2
p (10)
where the subscript low denotes a low concentration property.
As such, the structure factor proﬁle can be obtained by
normalizing the intensity proﬁle by the low-concentration data
according to
=S q I q
I q
c
c
( )
( )
( )eff low
low
(11)
Using eq 11 requires that there are no protein conformational
changes as a function of protein concentration. Conforma-
tional changes would be reﬂected by diﬀerences in the
normalized I(q)/c proﬁles over a range, where Seff(q) ∼ 1
corresponding to q > 1.0 nm−1, which is not observed for
rHSA solutions studied here.
For nonspherical particles, Seff(q) is given by an ensemble
average over all possible orientations and separations between
particles i and j
= +
∑ ⟨ Ω * Ω [ · − ]⟩
⟨| Ω | ⟩
≠ Ω Ω
Ω
q q
q
S q
N
F F k r r
F
( ) 1
1 ( , ) ( , ) exp i ( )
( , )
i j j j i i j i r
j j
eff
, ,
2
ij j i
j
(12)
where N is particle number. The main purpose of measuring
Seff is to obtain information about the solution structure as
characterized in terms of the true structure factor, which is
deﬁned in terms of an ensemble average over center-of-mass
positions between particles
∑= + ⟨ [ · − ]⟩
≠
S q
N
k r r( ) 1
1
exp i ( )
i j
j i rij
(13)
For spherical particles, the apparent and true structure factors
are equal to each other because there is no orientational
dependence of the scattering factor, Fj. For anisotropic
particles, the measured structure factor can be related to the
true structure factor, S(q), using the decoupling approxima-
tion, which assumes that there are no orientational correlations
between particles. The approximation is given by
β= + [ − ]S q S q( ) 1 ( ) 1eff DA (14)
where the decoupling parameter is deﬁned as βDA = ⟨|Fj(q)|⟩Ωj
2 /
⟨|Fj(q)|
2⟩Ωj.
The limitations of ﬁtting SAXS data with the decoupling
approximation or using spherical models have been examined
using molecular simulations of ellipsoids with aspect ratios
ranging from 0.333 to 3.51 For aspect ratios less than 0.5 or
greater than 2, the simulated Seff(q) proﬁle only equals the true
structure factor for the ellipsoids in the range q(ab2)1/3 ≲ 2,
where a and b correspond to the radii along and perpendicular
to the symmetry axis, respectively. The deviations between the
structure factor proﬁles at larger q grow with increasing volume
fraction, leading to a shift in the major peak in Seff(q) to a
higher q value than that occurring in S(q). Because the peak
location is inversely related to the averaged particle center-to-
center separation, matching the peak position can lead to
underestimating key length scales in intermolecular correla-
tions. In addition, for ellipsoids with aspect ratios less than 0.5,
there is an occurrence of a second peak at higher q in Seff(q)
that does not reﬂect any characteristic length scale observable
from S. For these particles, the decoupling approximation does
not provide any additional accuracy due to strong orientational
couplings at close center-to-center separation. Fitting form
factor models to experimentally derived SAXS data indicates
that HSA has a similar shape to an oblate ellipsoid with
dimensions equal to 17 × 42 × 42 Å3,41 which corresponds to
an aspect ratio of approximately 0.4. To avoid any artifacts of
these assumptions, only the region in the Seff(q) proﬁle
corresponding to q(ab2)1/3 ≲ 2 or equivalently q < 0.06 Å is
used in our ﬁtting.
SAXS Analysis. All calibrations and corrections of the
SAXS data were done using the in-house software Bli911-4.52
Buﬀer averaging and subsequent subtraction prior to data
analyses were done in Primus.53 The ATSAS program package
version 2.454 was used for further data analysis. Evaluation of
the Guinier region was performed within Primus. The form
factor for each buﬀer condition, P(q), was derived from
merging data at low and high protein concentrations in the
same buﬀer conditions. The pair distribution function, p(r),
was evaluated using the interactive program GNOM.55 An
overview of the samples measured by SAXS, the SAXS
scattering data, and the data treatment parameters are provided
in Tables S1−S4 and Figure S1, Supporting Information.
The eﬀective structure factors, Seff(q), were derived by
dividing the scattering intensity by the experimentally derived
form factor for the corresponding buﬀer condition following
the procedure deﬁned by eq 11.
■ RESULTS AND DISCUSSION
Protein−Protein Interactions Probed by SLS Scatter-
ing Indicate that the High Salt Behavior Is Only due to
Excluded Volume Forces. The SLS data were used for
determination of the osmotic second virial coeﬃcient, B22, and
the molecular weight. All measurements of molecular weight
were on the order of 70.0 ± 3.5 kDa, indicating monodisperse
samples. B22 values plotted as a function of ionic strength are
shown in Figure 1 for solutions either in octanoate_pH7.0 or
in phosphate_pH6.2 along with a line of best ﬁt to the
octanoate_pH7.0 data. The main eﬀect of increasing ionic
strength up to 100 mM is to screen electrostatic repulsion,
which leads to the decrease in B22 values. Over this range, the
ionic strength dependence of protein−protein interactions in
terms of B22 can be rationalized in terms of an electric double-
Figure 1. B22 values plotted vs ionic strength for solutions in
octanoate_pH7.0 (closed circles) and phosphate_pH6.2 (open
circles). The solid line is the best ﬁt of octanoate_pH7.0 data
corresponding to Z = −16.3e and B22hs = 10.5 × 10−5 mL mol/g2.
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layer force.16,17,21,22 The line of best ﬁt shown in Figure 1 has
been obtained by ﬁtting the octanoate_pH7.0 data to eq 4
using the double-layer potential for w as given by eq 1. The ﬁt
parameters are the limiting value for B22 at high ionic strength
given by the hard sphere value B22
hs = 10.5 × 10−5 mL mol/g2
and a net charge value Z equal to −16.3e. The latter is in good
agreement with the experimental value equal to −14e obtained
from potentiometric titration data at pH 756 (Tanford and
Buzzell,57 obtained −13e at pH 7.3) indicating that the DLVO
potential provides an adequate representation of the electro-
static contribution to the protein−protein interactions.
In modeling the protein−protein interactions, we neglected
any contributions from a short-ranged protein−protein
attraction so that the contribution to B22 at high salt
concentration is only from excluded volume forces. This
assumption can be checked by comparing the ﬁt value for B22
hs
versus a theoretical estimation of the parameter. The excluded
volume for anisotropic-shaped proteins can be approximated
by the excluded volume for a hypothetical sphere with the
same hydrodynamic diameter as the protein.58 The literature
value for the hydrodynamic diameter of BSA is approximately
74 Å,59 which corresponds to an excluded volume contribution
in experimental units equal to 11.1 × 10−5 mL mol/g2. A
similar value was reported independently36 through calculating
the excluded volume for an ellipsoid that gives the best ﬁt to
the form factor data for BSA. The theoretical value is indeed
very close to our results for B22 at 500 mM sodium chloride
concentration equal to 10.8 ± 0.7 × 10−5 and 11.1 ± 0.5 ×
10−5 mL mol/g2 for octanoate_pH7.0 and phosphate_pH6.2,
respectively, which, in turn, are similar to the ﬁt value of B22
hs
because electrostatic interactions are suﬃciently screened
under these conditions. The close agreement between the
theoretical estimate and the high ionic strength data for B22
indicates that there is a negligible contribution from the short-
ranged attraction. This deduction is consistent with SAXS
studies of BSA and HSA under low- to moderate-ionic-strength
conditions, which do not require any short-ranged protein−
protein attraction in models for ﬁtting to structure factor
proﬁles.35,41,44 This behavior is in direct contrast to SAXS
studies of lysozyme, which require including a short-ranged
attraction in models for capturing SAXS data even under
conditions where the net protein−protein interaction is
repulsive and S(0) is less than 1.44,60
The measured values for the osmotic compressibility (or
equivalent S(0)−1) obtained from SLS are compared in Figure
2 for the same solution conditions used to measure the B22
values. For the octanoate_pH7.0, there is a decrease in osmotic
compressibility with increasing ionic strength due to screening
the electrostatic repulsion. However, there is very little change
between the curves with 145 mM NaCl versus 500 mM NaCl
as the electrostatic forces have been suﬃciently screened. The
runs in phosphate_pH6.2 also follow the trends expected from
considering the B22 values and the eﬀect of electrostatic
interactions, which indicate that the protein−protein repulsion
is greater than that at pH 7, 145 mM NaCl, but less than that
at 50 mM NaCl and pH 7. The osmotic compressibility is
bounded by the corresponding curves for these solution
conditions. The high salt concentration run at pH 6.2 agrees
very well with the high salt run at pH 7.0 as the electrostatic
interactions have been screened and there is very little eﬀect of
changing the net charge on the protein due to reducing the pH
from 7.0 to 6.2. This is also expected from the B22 studies
shown in Figure 1, which are similar under the high salt
conditions.
Decoupling Excluded Volume and Electrostatic
Forces from Fitting to Low-q Region of S(q). In Figure
3a−e are shown the measured static structure factor proﬁles
Seff(q) for rHSA as a function of salt concentration in
octanoate_pH7.0 (Figure 3b) and in phosphate_pH6.2
(Figure 3d) with a nominal protein concentration of ∼40 g/
L, and as a function of protein concentration in octanoate_-
pH7.0_I153 (Figure 3a), phosphate_pH6.2_I66 (Figure 3c),
and citrate_pH6.5_I274 (Figure 3e). In all cases, the
extrapolated values Seff(0) are less than 1, indicating the
presence of net repulsive protein−protein interactions. The
eﬀect of the electrostatic repulsion is apparent from the
increase in S(0) values with increasing ionic strength as shown
in Figures 2 and 3. The eﬀect is much more dramatic in
octanoate_pH7.0 because the initial ionic strength is 18 mM,
whereas in citrate_pH6.5, the lowest ionic strength curve
corresponds to 66 mM. With increasing protein concentration,
the S(0) values decrease, which is expected for a system that
exhibits only repulsive interactions.
The solid lines shown in Figure 3 are obtained from ﬁtting
data for q values less than 0.06 Å−1, which is the region where
Seff(q) is equal to the true structure factor S(q).
51 We have
included only a small q range to avoid any artifacts that arise
from including eﬀects from orientational correlations on
Seff(q), but this limits the certainty in the estimates of ﬁtting
parameters. As such, we only consider ﬁtting one parameter to
the data using two diﬀerent approaches. First, the ﬁtting
includes the hard sphere potential and the double-layer force,
where the protein charge is treated as a ﬁtting parameter and
the hard sphere diameter is constrained to a value of 67 Å,
which has been shown previously to provide a good ﬁt to
SAXS data for BSA at high protein concentration.41 The
screening length is determined from eq 2 using the
experimental ionic strength. This approach is referred to as
the electrostatic model. The second approach only uses a hard
sphere potential and does not include any long-ranged
repulsive interactions. As such, the diameter is treated as a
ﬁtting parameter. The results of the ﬁtting are shown in Tables
12−3 along with the reduced χ2 values.
The results as a function of ionic strength can be used to
examine the role of repulsive electrostatic interactions in the
ﬁtting. Previous studies of BSA have shown that thermody-
Figure 2. Osmotic compressibility measured using SLS in
octanoate_pH7.0 (red symbols) or phosphate_pH6.2 (blue symbols)
at diﬀerent sodium chloride concentrations as denoted in the legend.
The lines are drawn as a guide to the eye.
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namic properties (e.g., osmotic pressure, osmotic compressi-
bility) can be accurately reproduced up to high protein
concentrations using only a hard sphere model, where the
diameter is tuned to account for any electrostatic repul-
sion.28,61 Similarly, phase diagrams of protein solutions can be
accurately reproduced using an eﬀective diameter chosen to
account for all repulsive contributions to the interaction
potential.62,63 As such, a key question is whether our ﬁtting can
discriminate a model including the electric double-layer force
from a model including only hard sphere interactions. The
relative accuracy of our ﬁtting approaches can be ascertained
from the ratio of χ2 values obtained from ﬁtting data to the
hard sphere model versus the electrostatic model, rχ = χhs
2 /χel
2 .
This ratio is plotted versus ionic strength in Figure 4 for the
runs in phosphate_pH6.2 and octanoate_pH7.0. At low-ionic-
strength conditions, the electrostatic model provides a much
more accurate ﬁt, but with increasing ionic strength above 200
mM, the accuracies become similar as the ratio approaches 1
due to suﬃcient screening of the electrostatic interactions. This
is reﬂected by the B22 measurements at 500 mM ionic strength,
which are equal to the hard sphere value within the
experimental certainty, whereas the measured B22 value in
Figure 3. Selected structure factor proﬁles Seff(q) obtained from SAXS measurements for solutions in octanoate_pH7.0 (a) 145 mM NaCl, ∼20 to
∼150 g/L rHSA, (b) 40 g/L rHSA, 50−500 mM NaCl; in phosphate_pH6.2 (c) no added salt, ∼30 to ∼180 g/L rHSA, (d) 0−500 mM NaCl, 40
g/L rHSA; and (e) in citrate_pH6.5, 40−260 g/L rHSA. The orange lines correspond to the electrostatic ﬁtting in phosphate_pH6.2 and
octanoate_pH7.0, and to the hard sphere ﬁtting for the runs in citrate_pH6.5_I274.
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octanoate_pH7.0 with 200 mM sodium chloride is only 10%
larger in magnitude. Fitting the Seff(q) proﬁles taken with 500
mM NaCl to the hard sphere model gives a diameter equal to
71 and 69 Å in octanoate_pH7.0 and phosphate_pH6.2,
respectively. Both these values are slightly below the hard
sphere diameter equal to 74 Å deduced from the B22
measurements. We argue below that this discrepancy in part
arises due to assuming that HSA is a sphere when ﬁtting the
structure factor at higher protein concentrations.
The ﬁtting also provides realistic values for the net charge of
rHSA as a function of ionic strength. The values obtained in
octanoate_pH7.0 are only slightly larger than the ones
obtained in phosphate_pH6.2 reﬂecting an expected decrease
in net negative charge. The absolute values in phospha-
te_pH6.2 remain relatively constant and approximately equal
to −9e, whereas in octanoate_pH7.0, there is a slight increase
from −10e to −17e when increasing ionic strength from 20 to
200 mM. The increase has been previously observed by ﬁtting
the model to SAXS data using the same hard sphere diameter
and attributed to an increase in chloride-ion binding.41,64 At
high ionic strengths of 500 mM, the ﬁt value of charge is much
larger, but the electrostatic contribution to the interaction
potential is very small due to the ionic screening. This
condition corresponds to the case when the ﬁtting cannot
discriminate between the electrostatic model or a hard sphere
model with a slightly larger diameter.
The experiments in citrate_pH6.5_I274 were pushed to
much higher protein concentrations with a total ionic strength
Table 1. Parameters Obtained from Fitting to Seff(q) in Octanoate_pH7.0
ionic strength (mM) [NaCl] (mM) [rHSA] (g/L) Z (e)a χ2 a σ (Å)b χ2 b
153 145 22.6 16.0 ± 0.2 2.14 73.5 ± 0.2 3.09
153 145 41.8 14.9 ± 0.1 3.64 72.2 ± 0.1 6.4
153 145 83.0 15.5 ± 0.2 11.0 71.6 ± 0.1 19.5
153 145 143.8 15.5 ± 0.2 17.9 70.5 ± 0.1 26.4
163 10 45.8 10.2 ± 0.1 33.2
173 20 44.7 11.7 ± 0.1 23.4
203 50 45.6 13.5 ± 0.1 9.43 78.8 ± 0.2 32.4
253 100 44.5 15.4 ± 0.1 4.27 75.1 ± 0.1 10.0
298 145 41.8 14.9 ± 0.1 3.64 72.2 ± 0.1 6.41
353 200 42.3 17.1 ± 0.2 2.83 71.6 ± 0.1 4.27
653 500 38.4 27.5 ± 0.3 1.59 70.7 ± 0.1 1.84
aIndicates that the DLVO potential is included in the model where Z is the ﬁt parameter. bIndicates ﬁtting with only a hard sphere potential, where
σ is the ﬁtting parameter.
Table 2. Parameters Obtained from Fitting to Seff(q) in Phosphate_pH6.2
ionic strength (mM) [NaCl] (mM) [rHSA] (g/L) Z (e)a χ2 a σ (Å)b χ2 b
66 0 23.8 5.54 ± 0.4 23.8
66 0 32.7 9.4 ± 0.1 2.98 72.8 ± 0.2 6.15
66 0 41.1 10.0 ± 0.1 3.29 73.3 ± 0.2 7.98
66 0 63.2 10.1 ± 0.1 4.46 72.7 ± 0.2 12.5
66 0 107.4 9.4 ± 0.1 6.36 71.1 ± 0.1 16.2
66 0 181.8 8.4 ± 0.2 8.23 68.3 ± 0.1 28.5
76 10 39.9 9.7 ± 0.1 2.22 72.2 ± 0.2 4.74
86 20 38.9 10.1 ± 0.1 2.42 71.9 ± 0.2 4.53
116 50 39.3 8.3 ± 0.3 2.77 69.4 ± 0.2 3.59
166 100 38.2 10.5 ± 0.3 1.58 69.5 ± 0.1 1.97
216 150 34.2 10.0 ± 0.4 1.68 68.6 ± 0.1 1.87
266 200 35.1 10.9 ± 0.4 1.49 68.5 ± 0.1 1.65
566 500 30.7 23.4 ± 0.5 0.97 69.4 ± 0.1 1.01
aIndicates that the DLVO potential is included in the model, where Z is the ﬁt parameter. bIndicates ﬁtting with only a hard sphere potential, where
σ is the ﬁtting parameter.
Table 3. Parameters Obtained from Fitting to Seff(q) in Citrate_pH6.5
ionic strength (mM) [NaCl] (mM) [rHSA] (g/L) Z (e)a χ2 a σ (Å)b χ2 b
274 0 28.6 17.7 ± 0.4 0.96 70.6 ± 0.2 0.89
274 0 38.8 16.6 ± 0.3 0.89 70.0 ± 0.1 0.89
274 0 49.7 17.7 ± 0.3 1.39 69.9 ± 0.1 1.05
274 0 91.5 17.5 ± 0.2 1.20 69.5 ± 0.1 1.55
274 0 129.5 10.2 ± 0.6 7.27 67.6 ± 0.1 8.88
274 0 177.9 66.6 ± 0.1 15.7
274 0 259.8 65.0 ± 0.1 24.1
274 0 315.1 64.1 ± 0.1 18.0
aIndicates that the DLVO potential is included in the model, where Z is the ﬁt parameter. bIndicates ﬁtting with only a hard sphere potential, where
σ is the ﬁtting parameter.
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equal to 274 mM. At this ionic strength, the eﬀect of
electrostatic interactions is expected to be small so that the
hard sphere model should provide an adequate ﬁtting. This
indeed is the case as χ2 values are similar for both ﬁttings for
the runs at lower protein concentration. At protein
concentrations less than 100 g/L, the ﬁtting is similar to
what was found in octanoate_pH7.0_I153, where the ﬁt
charge is similar to −17e when using the electrostatic model or
the diameter is near to 70 Å for the hard sphere model. With
further increasing protein concentration, the ﬁt diameter
steadily decreases to a value of 64 Å at a protein concentration
of 315 g/L. At this limit, ﬁts to the electrostatic model are not
possible when ﬁxing the diameter to 67 Å because the osmotic
compressibility predicted by the hard sphere model is greater
than the measured value for 1/S(0). Matching the
experimental data requires either reducing the diameter
below 67 Å or introducing a short-ranged protein−protein
attraction. This discrepancy likely arises due to ﬁtting the
structure factor of an anisotropic-shaped protein with a
spherical model. The spherical assumption was examined in
a computational study for a monoclonal antibody by
comparing the structure factor proﬁles and osmotic compres-
sibility of a three-bead model for the protein to that of an
equivalent hard sphere with the same osmotic second virial
coeﬃcient.65 For excluded volume systems, the osmotic
compressibility is proportional to the fraction of overlapping
particle conﬁgurations. Because the three-bead model and the
sphere have the same osmotic second virial coeﬃcient, the
osmotic compressibility is similar at low protein concen-
trations, where only two-body interactions are signiﬁcant. With
further increasing protein concentration, the osmotic compres-
sibility for the sphere is always greater than that for the bead
model because there are more n-particle nonoverlapping
conﬁgurations available to the anisotropic model versus the
sphere of the same excluded volume. Because the three-bead
model has a similar ﬂattened geometry to an oblate ellipsoid, it
is likely that a similar argument applies to albumin. Indeed, in
the study by Greene et al.,51 the sphere that best matches the
oblate ellipsoidal structure factor at high packing fractions (e.g.
greater than 20%) is smaller than the equivalent sphere with
the same excluded volume. Our ﬁnding that a smaller sphere is
needed to model HSA at high protein concentrations is also
consistent with a molecular simulation study, indicating that
the best-ﬁt diameter to SAXS data is 63.6 Å, which is much less
than the excluded volume diameter.35
Osmotic Compressibility Curves Measured by SAXS
and SLS Are Similar. SLS and SAXS provide complementary
techniques for estimating S(0) as both approaches rely on
assumptions about the angle dependence of the scattered light.
For the SAXS data, ﬁtting is required to extrapolate the Seff(q)
proﬁle to the long-wavelength limit from data obtained for q-
values greater than 0.01 Å−1, whereas the SLS experiment
assumes no q-dependence of scattered light for q less than
approximately 0.001 Å−1. As a check of the assumptions,
Figure 5 shows a comparison of the measured values of 1/
Seff(0) by SLS to those obtained from the ﬁts to the SAXS data
in octanoate_pH7.0_I153 and in phosphate_pH6.2_I66. We
ﬁnd a very good agreement between the methods for both
solutions. The general rule of thumb is that the wavelength
should be greater than 20 times the characteristic correlation
length in the protein solution for neglecting the angle
dependence of scattered light. If the main contribution to
protein−protein interactions is only from excluded volume
interactions, the correlation length is expected to be on the
order of the size of a protein molecule, about 70 Å, which is
much less than the wavelength of laser light equal to 658 nm.
The eﬀects of electrostatic interactions on the correlation
length are expected to be negligible even at the lower ionic
strength conditions in phosphate_pH6.2_I66, where the
screening length is on the order of 1.2 nm.
Oblate Ellipsoidal Model Is More Accurate at
Describing the Osmotic Compressibility from Low to
High Protein Concentration. In Figure 6, S(0)−1 curves
obtained from SLS in solutions with 500 mM NaCl in
phosphate_pH6.2 or octanoate_pH7.0 are compared against
the values obtained for citrate_pH6.5_I274 from SAXS.
Because the data agree very well with the behavior in the
other buﬀers with 500 mM NaCl, we expect that an excluded
volume model should be capable of describing the data
obtained for citrate_pH6.5_I274. As such, these can be used to
test the accuracies of using an ellipsoidal versus spherical
model. We use the virial equation including the ﬁrst 10 terms
in the expansion for the hard sphere equation of state, given by
∑βρ ρ=
Π = +
=
−Z B1
i
i
i
2
10
v ( 1)
(15)
where Bi
v corresponds to the ith virial coeﬃcient (noting that
B22
v ≡ B2v). The calculated pressure from the 10-term virial
Figure 4. Ratio of χ2 values obtained from ﬁtting data to the hard
sphere model and the electrostatic model: rχ = χhs
2 /χel
2 . Solid sphere:
octanoate_pH7.0; open sphere: phosphate_pH6.2.
Figure 5. Comparison of osmotic compressibility proﬁles as a
function of rHSA concentration obtained from SAXS (red symbols)
to those obtained by SLS (blue symbols) for phosphate_pH6.2_I66
(triangles) or octanoate_pH7.0_I153 (circles).
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expansion agrees with simulated data for hard spheres with a
precision of ΔZ < 0.003 compared to molecular simulations up
to a packing fraction η ≡ πρσ3/6 < 0.35.
The ellipsoidal model is based on the equation of state
derived by Vega.66 For oblate ellipsoids with relative
dimensions given by 1 × 2.5 × 2.5, the analytical calculations
agree with simulation data up to packing fractions equal to
0.45.67 The Vega equation of state is
β
ρ
η η η η
η η η
η
Π = + * + * + * + *
+ [ − − − −
− ]
B B B B
B
Z
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CS 2 3
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where the nth dimensionless virial coeﬃcient is given by Bn* =
Bn
v/Vn−1, V is the volume of the ellipsoid, and the packing
fraction is given by η = ρV. The dimensionless virial
coeﬃcients are functions of the mean radius of curvature for
the ellipsoid R and the ellipsoid surface area S and volume V.
The mathematical expressions to calculate the geometric
properties, R, S, and V, and the virial coeﬃcients are given in
ref 67.
In Figure 7, the best ﬁts of the spherical and the ellipsoidal
model to the experimental data in citrate_pH6.5_I274 are
shown. For the spherical model, the only ﬁtting parameter is
the hard sphere diameter σ equal to 64.7 Å. In the ellipsoidal
model, we rely on the geometric structure determined from
ﬁtting to the form factor of albumin, which is an oblate
ellipsoid with dimensions of 17 × 42 × 42 Å3.41 In the ﬁtting,
each of the dimensions are multiplied by a constant factor f,
which is necessary to account for the eﬀect of surface
roughness on the excluded volume calculation. The form
factor should correspond to the actual volume of albumin
including a hydration layer. However, the excluded volume is
also increased due to the surface roughness over a smooth
shape with the same actual volume.68 As it is not possible to
exactly quantify this eﬀect, f is treated as a ﬁtting parameter.
The best ﬁt to the ellipsoidal model is shown by the solid curve
in Figure 7. The ellipsoidal model appears to provide a better
representation of the data as the best-ﬁt line corresponding to
the 10-term virial equation has too much curvature, and as a
consequence, underestimates the osmotic compressibility at
moderate protein concentrations.
The improved accuracy of the ellipsoidal model becomes
more evident when also considering the dilute solution
behavior. The second virial coeﬃcient calculated for the
best-ﬁt spherical model is equal to 7.8 × 10−5 mL mol/g2,
whereas the corresponding value for the ellipsoidal model is
equal to 9.6 × 10−5 mL mol/g2. The latter is much closer to
the excluded volume contribution to B22 estimated from the
SLS experiments equal to 10.5 × 10−5 mL mol/g2. Figure 7
also contains the curves for either model when the ﬁtting
parameters are chosen to match the excluded volume
contribution to B22. The ellipsoidal model prediction, as
expected, is much more accurate; the close agreement to the
experimental data indicates that the thermodynamic properties
for albumin in concentrated solutions can be predicted using
the oblate model when parameterized against a dilute solution
parameter, B22.
Previous studies have shown that the hard sphere model
provides accurate ﬁts to osmotic pressure data up to BSA
concentrations of 450−500 g/L in solutions containing 150
mM NaCl for a range of pH values between 4.5 and 7.4.61,69
Of most relevance to the work here is the pH 7.4 data, which
were reproduced using a diameter of 69 Å by ﬁtting the data to
a six-term virial equation. These data are reproduced in Figure
8 including the best ﬁts using the ellipsoidal model and the
virial equation including 6 or 10 terms. A similar pattern to the
structure factor data is observed, where the spherical model has
more curvature than the ellipsoidal model, which leads to an
underprediction for the compressibility at intermediate protein
concentrations. This eﬀect is more pronounced by increasing
the precision of the virial expansion from using 6 versus 10
terms. The calculated virial coeﬃcients for the best ﬁts are 12.1
and 8.2 × 10−5 mL mol/g2 for the ellipsoidal and spherical
models, respectively. While we have not measured the B22
value at the pH 7.4 solution condition, which only included
NaCl at a concentration of 150 mM with no buﬀer ions, the
value should be similar to our experiment in octanotate_-
pH7.0_I154. According to the potentiometric titration curve
measured by Tanford et al.,70 there is an increase of net
negative charge of ∼4e for this pH change (7.0−7.4). The
corresponding value of B22, as calculated by using the DLVO
Figure 6. Measured values for S(0)−1 as a function of rHSA
concentration obtained from SLS for samples at high salt conditions
in phosphate_pH6.2 (blue squares) and octanoate_pH7.0 (red
circles) and from SAXS for samples in citrate_pH6.5_I274 (black
triangles).
Figure 7. S(0)−1 values from SAXS experiments in citrate_-
pH6.5_I274 corresponding to the ﬁlled circles have been ﬁtted to
the 10-term virial expansion (dashed red line) and the ellipsoid model
(dashed blue line). Predictions based on using parameters derived
from matching B22 = 10.5 × 10
−5 mL mol/g2 are shown for the 10-
term virial expansion (solid red line) and the ellipsoid model (solid
blue line). Fit parameters are shown in the legend.
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potential, is of the order 13.0 × 10−5 mL mol/g2, which
provides a close agreement to the ellipsoidal model ﬁt.
■ CONCLUSIONS
The key ﬁnding from our work is that the thermodynamic
properties of HSA (as well as BSA) are more accurately
reproduced with an ellipsoidal versus spherical equation of
state, which initially became evident from the decrease in hard
sphere diameter values obtained from ﬁtting the Seff(q) proﬁles
in citrate_pH6.5_I274. The spherical model, when para-
meterized on the dilute solution measurement, overpredicts
the osmotic compressibility for excluded volume systems, an
eﬀect that grows with increasing protein concentration when
higher-order virial terms contribute more to the thermody-
namic properties. The ellipsoidal model, on the other hand,
provides a more accurate extrapolation of the dilute solution
data. This study has only been possible because there are no
observable eﬀects of short-ranged attractions on HSA so that
the behavior at moderate ionic strengths reﬂects only excluded
volume interactions. Nevertheless, the work is still signiﬁcant
for systems that exhibit short-ranged attraction. For instance, if
an osmotic compressibility curve, or an eﬀective structure
factor proﬁle, is ﬁtted to a spherical interaction model, the
ﬁtted value of the short-ranged attraction will likely be larger
than the true value to compensate for overpredicting the
excluded volume contribution.
A key motivation for this work was to establish if there are
any eﬀects of typically used formulation conditions on the
stability of HSA, in particular, slight changes in pH and the
eﬀect of adding trehalose. When comparing the runs in
phosphate_pH6.2 and in octanoate_pH7.0, the diﬀerences can
be rationalized in terms of changed electrostatic interactions
due to changing the net charge of the protein. The ﬁt values for
the net charge are 10e in phosphate_pH6.2 versus 15e in
octanoate_pH7.0 over the ionic strength range of 50−200 mM
consistent with the expected change in the protonation state of
the protein as measured by Tanford et al.70 In both cases, there
is a large increase at 500 mM NaCl, which, although not
evident from the B22 measurements, might reﬂect a slight
increase in protein−protein repulsion. As such, it does not
appear that the excipients, trehalose and polysorbate, used in
the buﬀer impact the protein−protein interactions for HSA.
This is partly because the rHSA we use is saturated with
octanoate and polysorbate-defatted rHSA will behave diﬀer-
ently.71 Indeed, osmotic second virial coeﬃcient studies for
lysozyme solutions in sodium chloride indicate that trehalose
weakens short-ranged protein−protein attractive forces.72
However, our study indicates that these forces are absent,
which might be why rHSA, saturated with octanoate and
polysorbate, behavior is insensitive to the nonionic compo-
nents of the formulation buﬀer.
It is clear that HSA is repulsive due to its large net charge.
We speculate that this could be the physical reason for the
stabilizing eﬀect of HSA on other proteins. HSA is screening
itself and thereby creating a network, making it possible for
other proteins to distribute themselves among the HSA
molecules, preventing aggregation.
■ METHODS
Yeast-derived rHSA in the form of 100 mg/mL Recombumin
supplied by Albumedix Ltd. was used.
Solvent Systems. Three distinct pharmaceutically relevant
solvent systems were used (for an overview, see Table 4). The
ionic strength of the buﬀer is determined from summing over
all of the ionic components according to ionic strength =
∑icizi2, where ci and zi are the molar concentration and valency
of ion i, respectively. Citrate_pH6.5_I274 is mimicking to the
buﬀer of rituximab in MabThera. This buﬀer has a high ionic
strength. Octanoate_pH7.0_I153 is mimicking the Recombu-
min buﬀer, and phosphate_pH6.2_I66 is similar to the buﬀer
of bevacizumab in Avastin where the ionic strength is quite low
compared to the other two buﬀers. Concentration series were
measured in all three buﬀers, and additionally, the eﬀect of
varying ionic strength was studied in octanoate_pH7.0 and
phosphate_pH6.2, where the ionic strength was adjusted by
varying the concentration of NaCl.
Preparation of Protein Samples and Buﬀers. Buﬀers
were exchanged by dialysis in three shifts over 3 days at 4 °C
applying gentle stirring. The dialysis was performed with Slide-
A-Lyzer Dialysis G2 Cassettes from Thermo Scientiﬁc with the
appropriate molecular mass cutoﬀ value. The individual
samples were prepared by diluting or concentrating the
dialyzed sample. Samples with varying salt concentrations
were prepared from buﬀer stock solutions with a high NaCl
content by adding an appropriate amount of buﬀer to the
individual samples. Importantly, buﬀers for buﬀer subtraction
were also prepared to match the diﬀerence in NaCl content.
Further concentration after dialysis was done using Pall
Nanosep centrifugal device with Omega membrane 10 K
cutoﬀ. Concentration determinations were performed with the
NanoDrop 1000 Spectrophotometer from Thermo Scientiﬁc at
Figure 8. Compressibility factor obtained from the experimental data
taken by Vilker et al.69 along with the ﬁts for the ellipsoidal model
(black line) and the virial equation of state with either 6 terms (red
line, denoted by *) or 10 terms (blue line). Fit parameters are shown
in the legend.
Table 4. Solvent Systems
buﬀer constituents pH IS (mM)
citrate_pH6.5_I274 154 mM NaCl, 25 mM Na3C6H5O7·2H2O, 0.07% Tween 80 6.5 274
octanoate_pH7.0_I153 145 mM NaCl, 8 mM octanoate, 0.05 g/L Tween 80 7.0 153
phosphate_pH6.2_I66 42 mM NaH2PO4·2H2O, 8 mM Na2HPO4, 159 mM α,α-trehalose·2H2O, 0.4 g/L Tween 20 6.2 66
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280 nm. The extinction coeﬃcient was calculated to be 34 445
cm−1 M−1, with the ProtParam73 tool from ExPASy.org74 using
the primary sequences of HSA.
SAXS Data Collection. SAXS data collection was
performed at the MAX II synchrotron, MAX IV laboratories
at beamline I911-SAXS, Sweden.52 The sample detector
distance and the direct beam position were calibrated using
silver behenate. Measurements on pure water were used to get
the data on an absolute scale. Buﬀers were measured both
before and after each sample and averaged before subtraction.
The sample size was approximately 50 μL injected manually in
a ﬂow cell.
Measurements were performed on a series of rHSA samples
at various concentrations prepared as described above. The
protein concentrations measured in the individual buﬀers are
listed in Tables S1 and S2 with respect to, respectively, rHSA
and NaCl concentrations at ﬁxed albumin concentration. Data
collection parameters are listed in Table S3.
SLS Data Collection. A Wyatt miniDAWN TREOS 3
angle detector was used for the SLS experiments. Samples were
injected using a syringe pump through an in-line 0.1 mm ﬁlter,
followed by the SLS ﬂow cell connected in series to a UV
Waters 2487 absorbance detector. We used a variable path
length UV ﬂow cell for accurate determination of protein
concentration. The path length was set to 0.05 cm such that
the absorbance of all protein solutions falls within the range
where the Beer−Lambert law is valid. SLS measurements at
high protein concentration were carried out using a Wyatt
NanoStar cuvette-based system with a low-volume quartz
cuvette. Both instruments use a 60 mW GaAs diode laser with
vertically polarized light at a wavelength of 658 nm.
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